ABOUT RIGHT OF ASSEMBLY

Right of Assembly is my personal blog. All opinions are my own. You can read more about me here.

DISCLOSURE

I am a ChromaDex shareholder, and an affiliate marketer. As a result, I will sometimes mention or recommend products that I endorse. I may earn a small commission from qualifying purchases if you were referred directly from this site and completed a purchase. [Thank you!] You can read more about our advertising, privacy, and data collection policies here. 

Cookies

This site uses cookies. Cookies are not required for site functionality. You can read more about how to opt-out of cookies here.

  • Shelly Albaum

Evidentiary Objections in IPR Trial


Steptoe has filed on behalf of Dartmouth/ChromaDex evidentiary objections to most of Elysium's exhibits. You can read them here:

Steptoe's Objections to Elysium's Exhibits

These are routine kinds of objections, and I don't express any opinion on the merits of the evidentiary issues.

However, this may be an indication that Steptoe is going to bring to bear maximum force in defending the Dartmouth/ChromaDex patent. It looks like Steptoe will not give an inch.

This will make the IPR trial expensive for Elysium to pursue, which would seem to be especially troubling for Elysium given that Elysium does not appear to have a much to gain from the exercise.

All of the '807 patent and at least one claim of the '086 patent have already survived IPR. As a result, the current version of Basis appears to infringe BOTH the '086 and '807 patents, no matter what happens at IPR (assuming Basis contains at least 25% nicotinamide riboside, and therefore would infringe claims in both patents relating to "isolated" NR).

Because continued prosecution of the IPR offers Elysium a high-cost and a low-reward, one would think that Elysium would be wanting to find some way to end the misery.

Or maybe not.

#CDXC #ChromaDex #ElysiumHealth #Litigation

191 views